CardioNerds(Amit Goyal,Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series.
In part 5, Dr. Packer shares his thoughts on the term “guideline directed medical therapy,” guidelines in general, and the challenges of using the ejection fraction to measure systolic function.
Dr. Packer discusses taking risks, upsetting people and the ridiculousness of humanity and how stand-up comedy helped contribute and shape his career in cardiovascular medicine. Dr. Packer also discusses how the study of afterload agents in heart failure and the discovery of tachyphylaxis with prazosin helped inspire a long and prosperous career in academic cardiology by changing the status quo.
Check out theCardioNerdsHeart Failure Success Series Pagefor more heart success episodes and content!
This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees fromAbbvie, Actavis,Amgen, Amarin,AstraZeneca,Boehringer Ingelheim,Bristol Myers Squibb, Casana, CSL Behring,Cytokinetics,Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company,Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics,Teva Pharmaceuticals USA Inc.and Theravance Biopharma Inc.
The Evolution of The Neurohormonal Hypothesis with Dr. Milton Packer: Part 1 – Taking Risks, Upsetting People, & Disrupting The Status Quo
CardioNerdsHeart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll
CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron!
Podcast: Play in new window | Download